SABS Straddle Strategy

SABS (SAB Biotherapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SABS (SAB Biotherapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $37.9M, a beta of 0.56 versus the broader market, a 52-week range of 1.6-6.6, average daily share volume of 770K, a public-listing history dating back to 2021, approximately 63 full-time employees. These structural characteristics shape how SABS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.56 indicates SABS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a straddle on SABS?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current SABS snapshot

As of May 15, 2026, spot at $3.67, ATM IV 176.30%, expected move 50.54%. The straddle on SABS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on SABS specifically: IV rank is unavailable in the current snapshot, so regime-based timing for SABS is inferred from ATM IV at 176.30% alone, with a market-implied 1-standard-deviation move of approximately 50.54% (roughly $1.85 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SABS expiries trade a higher absolute premium for lower per-day decay. Position sizing on SABS should anchor to the underlying notional of $3.67 per share and to the trader's directional view on SABS stock.

SABS straddle setup

The SABS straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SABS near $3.67, the first option leg uses a $3.67 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SABS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SABS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$3.67	N/A
Buy 1	Put	$3.67	N/A

SABS straddle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

SABS straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on SABS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on SABS

Straddles on SABS are pure-volatility plays that profit from large moves in either direction; traders typically buy SABS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

SABS thesis for this straddle

The market-implied 1-standard-deviation range for SABS extends from approximately $1.82 on the downside to $5.52 on the upside. A SABS long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. As a Healthcare name, SABS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SABS-specific events.

SABS straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SABS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SABS alongside the broader basket even when SABS-specific fundamentals are unchanged. Always rebuild the position from current SABS chain quotes before placing a trade.

Frequently asked questions

What is a straddle on SABS?: A straddle on SABS is the straddle strategy applied to SABS (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With SABS stock trading near $3.67, the strikes shown on this page are snapped to the nearest listed SABS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are SABS straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the SABS straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 176.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SABS straddle?: The breakeven for the SABS straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SABS market-implied 1-standard-deviation expected move is approximately 50.54%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on SABS?: Straddles on SABS are pure-volatility plays that profit from large moves in either direction; traders typically buy SABS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current SABS implied volatility affect this straddle?: Current SABS ATM IV is 176.30%; IV rank context is unavailable in the current snapshot.